Tier 4 — mechanistic

Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis

Marcia Cruz-Correa, Daniel A Shoskes, Patricia Sanchez, Rhongua Zhao, Linda M Hylind, Steven D Wexner, Francis M Giardiello
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2006 4(8):1035

Bibliography

PubMed
PMID 16757216
DOI
10.1016/j.cgh.2006.03.020
Funding
Indexed grant support: CA 53801 — NCI NIH HHS — United States; K07 CA092445 — NCI NIH HHS — United States; P50 CA 62924-10 — NCI NIH HHS — United States. The indexed list may not contain the complete funding declaration.
Competing interests
A competing-interest declaration was not available in the indexed record or the disclosure metadata used for this entry.

Study snapshot

DesignUncontrolled pilot case series
ModelHuman intervention research
Sample5 patients with familial adenomatous polyposis after colectomy
InterventionCurcumin 480 mg plus quercetin 20 mg three times daily
DurationMean 6 months
EndpointsSource-specific outcomes described in the key findings

What the study showed, in plain terms

Published in 2006, this source examined kidney and cancer research. Design: Uncontrolled pilot case series. Sample/model: 5 patients with familial adenomatous polyposis after colectomy. The exposure or intervention was Curcumin 480 mg plus quercetin 20 mg three times daily. Follow-up or treatment period: Mean 6 months.

Polyp number and size decreased from baseline in all five participants.

No placebo group, very small sample, and combined ingredients. The study does not establish cancer prevention or quercetin-only efficacy.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin Benefits: What Human Studies Actually Show. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Polyp number and size decreased from baseline in all five participants.
  • The recorded outcome domains were Source-specific outcomes described in the key findings.

What this study can and cannot tell us

  • No placebo group, very small sample, and combined ingredients. The study does not establish cancer prevention or quercetin-only efficacy.
  • A case report or series cannot estimate how often an event occurs or establish causality without alternative explanations and a suitable comparator.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition
D R Ferry et al. · Clinical cancer research : an official journal of the American Association for Cancer Research · 1996

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology